Heritage Trust Co Takes $2.26 Million Position in Pfizer Inc. (NYSE:PFE)

Heritage Trust Co purchased a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 85,228 shares of the biopharmaceutical company's stock, valued at approximately $2,261,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. PSI Advisors LLC grew its stake in shares of Pfizer by 1.4% during the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after acquiring an additional 385 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its holdings in Pfizer by 1.0% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock worth $1,027,000 after purchasing an additional 391 shares during the last quarter. D Orazio & Associates Inc. increased its stake in Pfizer by 5.5% in the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock valued at $200,000 after buying an additional 391 shares during the last quarter. Lipe & Dalton boosted its stake in shares of Pfizer by 17.7% during the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC grew its holdings in shares of Pfizer by 2.2% in the 4th quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock valued at $499,000 after acquiring an additional 401 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.06% of the company's stock.

Pfizer Stock Performance

Shares of PFE traded up $0.19 during mid-day trading on Monday, hitting $22.10. 61,845,565 shares of the company's stock were exchanged, compared to its average volume of 40,318,640. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market cap of $125.34 billion, a price-to-earnings ratio of 15.67, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The stock's 50-day simple moving average is $25.25 and its 200-day simple moving average is $26.38. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.10 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on PFE shares. Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group cut their price target on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a research note on Tuesday, April 8th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.07.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.